Destiny Pharma’s Neil Clark talks to Proactive about US Food and Drug Administration (FDA) approval process for a nasal gel to treat and prevent staphylococcal infections following surgery.
Work is underway on finalising the US study design and biostatistical analysis to clarify the final patient numbers required and the related costings and timeline.
